In this review we discuss how animal models have contributed to the understanding of pathological pathways that may be involved in the development of encapsulating peritoneal sclerosis. We review the various interventional procedures that, so far, have ameliorated disease progression in animals. Reviewing advancements in molecular biology and genetic technologies, we discuss how future experimental models may impact our understanding of the pathogenesis and treatment of this rare but complex disease.
WeberJ., MettangT., Mayer-WehrsteinR., KuhlmannU.[Continuous ambulatory peritoneal dialysis. Patient and method survival rate, peritonitis incidence and dialysis efficacy over 10 years].Dtsch Med Wochenschr1991; 116: 641–8.
2.
RigbyR.J., HawleyC.M.Sclerosing peritonitis: the experience in Australia.Nephrol Dial Transplant1998; 13: 154–9.
3.
de FreitasD., JordaanA., WilliamsR., AlderdiceJ., CurwellJ., HurstH.Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis.Perit Dial Int2008; 28: 271–6.
4.
JunorB.J., McMillanM.A.Immunosuppression in sclerosing peritonitis.Adv Perit Dial1993; 9: 187–9.
5.
KawaguchiY., KawanishiH., MujaisS., TopleyN., OreopoulosD.G.Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.Perit Dial Int2000; 20(Suppl 4): S43–55.
KawanishiH.Surgical treatment for encapsulating peritoneal sclerosis.Adv Perit Dial2002; 18: 139–43.
8.
de FreitasD.G., HurstH., JordaanA., TavakoliA., BrenchleyP.E.C., HutchisonA.J.Encapsulating peritoneal sclerosis (EPS) following renal transplantation [Abstract].Perit Dial Int2006; 26(Suppl 2): S116.
9.
FierenM.W., BetjesM.G., KorteM.R., BoerW.H.Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?Perit Dial Int2007; 27: 619–24.
10.
OulesR., ChallahS., BrunnerF.P.Case-control study to determine the cause of sclerosing peritoneal disease.Nephrol Dial Transplant1988; 3: 66–9.
11.
LoW.K., ChanK.T., LeungA.C., PangS.W., TseC.Y.Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol.Adv Perit Dial1990; 6: 79–84.
12.
FracassoA., ColiU., LandiniS., MorachielloP., RighettoF., ScanferlaF.Peritoneal sclerosis. Role of plasticizers.ASAIO Trans1987; 33: 676–82.
13.
NakamotoH., ImaiH., IshidaY., YamanouchiY., InoueT., OkadaH.New animal models for encapsulating peritoneal sclerosis—role of acidic solution.Perit Dial Int2001; 21(Suppl 3): S349–53.
14.
IshiiY., SawadaT., ShimizuA., TojimbaraT., NakajimaI., FuchinoueS.An experimental sclerosing encapsulating peritonitis model in mice.Nephrol Dial Transplant2001; 16: 1262–6.
15.
LevineS., SaltzmanA.Abdominal cocoon: an animal model for a complication of peritoneal dialysis.Perit Dial Int1996; 16: 613–16.
16.
IoH., HamadaC., RoY., ItoY., HiraharaI., TominoY.Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models.Kidney Int2004; 65: 1927–36.
17.
AbeK., MiyazakiM., YoshioY., NishinoT., FurusuA., HaradaT.Angiotensin II blockade ameliorates peritoneal fibrosis and angiogenesis in mouse experimental model of peritoneal fibrosis caused by chlorhexidine gluconate [Abstract].J Am Soc Nephrol2002; 13: 309A.
18.
SugaH., TeraokaS., OtaK., KomemushiS., FurutaniS., YamauchiS.Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.Exp Toxicol Pathol1995; 47: 287–91.
19.
HiraharaI., OgawaY., KusanoE., AsanoY.Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats.Nephrol Dial Transplant2004; 19: 1732–41.
20.
RoY., HamadaC., InabaM., IoH., KanekoK., TominoY.Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.Nephrol Dial Transplant2007; 22: 2838–48.
21.
NishinoT., MiyazakiM., AbeK., FurusuA., MishimaY., HaradaT.Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats.Kidney Int2003; 64: 887–96.
22.
YoshioY., MiyazakiM., AbeK., NishinoT., FurusuA., MizutaY.TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model.Kidney Int2004; 66: 1677–85.
23.
FukuokaN., SugiyamaH., InoueT., KikumotoY., TakiueK., MorinagaH.Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice.Am J Nephrol2008; 28: 661–8.
WilliamsJ.D., CraigK.J., TopleyN., von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
26.
BreborowiczA., KaronJ., KorybalskaK., MartisL., OreopoulosD.G.Functional properties of mesothelial cells after prolonged exposure to dialysate effluent.Adv Perit Dial1995; 11: 15–18.
27.
HiguchiC., TanihataY., NishimuraH., NaitoT., SanakaT.Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum.Ther Apher Dial2005; 9: 173–81.
28.
MargettsP.J., KolbM., GaltT., HoffC.M., ShockleyT.R., GauldieJ.Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function.J Am Soc Nephrol2001; 12: 2029–39.
29.
MargettsP.J., KolbM., YuL., HoffC.M., GauldieJ.A chronic inflammatory infusion model of peritoneal dialysis in rats.Perit Dial Int2001; 21(Suppl 3): S368–72.
30.
MargettsP.J., BonniaudP.Basic mechanisms and clinical implications of peritoneal fibrosis.Perit Dial Int2003; 23: 530–41.
31.
HiraharaI., KusanoE., YanagibaS., MiyataY., AndoY., MutoS.Peritoneal injury by methylglyoxal in peritoneal dialysis.Perit Dial Int2006; 26: 380–92.
32.
TopleyN.Animal models in peritoneal dialysis: more questions than answers?Perit Dial Int2005; 25: 33–4.
33.
ImaiH., NakamotoH., FucshimaR., YamanouchiY., IshidaY., SuzukiH.Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis.Adv Perit Dial2002; 18: 124–30.
34.
HoffC.M., MargettsP.J.Adenovirus-based transient expression systems for peritoneal membrane research.Perit Dial Int2006; 26: 547–58.
35.
HoffC.M., PiscopoD., SvatekJ.M., HolmesC.J., HondaK., MargettsP.J.Pilot study to establish an experimental animal model of EPS: potential contributing factors [Abstract].Perit Dial Int2004; 24(Suppl 2): S4.
36.
MatsuokaT., MaedaY., MatsuoK., NaikiY., TamaiY., SakaguchiM.Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis.J Nephrol2008; 21: 64–73.
37.
MaruyamaN., FukudaN., OkadaK., MatsumotoK.[Development of gene therapy for encapsulating peritoneal sclerosis by a chimeric DNA-RNA hammerhead ribozyme targeting TGF-beta1 mRNA].Nippon Jinzo Gakkai Shi2007; 49: 113–20.
38.
AroeiraL.S., AguileraA., Sanchez-TomeroJ.A., BajoM.A., del PesoG., Jimenez-HeffernanJ.A.Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions.J Am Soc Nephrol2007; 18: 2004–13.
39.
De VrieseA.S., TiltonR.G., MortierS., LameireN.H.Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia.Nephrol Dial Transplant2006; 21: 2549–55.
40.
NishiokaY., MiyazakiM., AbeK., FurusuA., HaradaT., OzonoY.Regeneration of peritoneal mesothelium in a rat model of peritoneal fibrosis.Ren Fail2008; 30: 97–105.
41.
BroganI.J., KhanN., IsaacK., HutchinsonJ.A., PravicaV., HutchinsonI.V.Novel polymorphisms in the promoter and 5’ UTR regions of the human vascular endothelial growth factor gene.Hum Immunol1999; 60: 1245–9.
42.
CambienF., RicardS., TroeschA., MalletC., GenerenazL., EvansA.Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study.Hypertension1996; 28: 881–7.
43.
RennerW., KotschanS., HoffmannC., Obermayer-PietschB., PilgerE.A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels.J Vasc Res2000; 37: 443–8.
44.
WatsonC.J., WebbN.J., BottomleyM.J., BrenchleyP.E.Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production.Cytokine2000; 12: 1232–5.
45.
GillerotG., GoffinE., MichelC., EvenepoelP., Van BiesenW., TintillierM.Genetic and clinical factors influence the baseline permeability of the peritoneal membrane.Kidney Int2005; 67: 2477–87.
46.
SummersA.M., BrenchleyP.E.C.An international encapsulating peritoneal sclerosis registry and DNA bank. Why we need one now.Perit Dial Int2006; 26: 559–63.
